Eleven states have reduced antipsychotic use in nursing home residents by at least 15%, meeting a CMS partnership goal set last year.
Eleven states have reduced antipsychotic use in nursing home residents by at least 15%, meeting a CMS partnership goal set last year.
In 2012 the Centers for Medicare and Medicaid Services (CMS) introduced the National Partnership to Improve Dementia Care in 2012, with a goal to reduce antipsychotic drug use by 15% by the end of this year. Data released on Nursing Home Compare by CMS demonstrated that the following states met or exceeded that goal: Alabama, Delaware, Georgia, Kentucky, Maine, North Carolina, Oklahoma, Rhode Island, South Carolina, Tennessee, and Vermont, according to CMS.
These nursing homes that are using less antipsychotics are providing more patient-centered treatment for dementia and other behavioral healthcare, according to the data on Nursing Home Compare. In 2010, the data showed that more than 17% of nursing home residents had received daily doses of antipsychotic medications that exceeded recommended levels.
“This important partnership to improve dementia care in nursing homes is yielding results,” reported Dr. Patrick Conway, CMS chief medical officer and director of the Center for Clinical Standards and Quality, in a statement. “We will continue to work with clinicians, caregivers, and communities to improve care and eliminate harm for people living with dementia.”
The data also show that long-stay nursing home residents have benefited from the initiative as the national prevalence of antipsychotic use in this patient population has been reduced by 9.1% in the first quarter of 2013, compared to the last quarter of 2011. Also, about 30,000 nursing home residents in the United States are no longer receiving these medications.
For additional information about the Partnership efforts, visit the Advancing Excellence in America’s Nursing Homes website.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More